Anzeige
Mehr »
Samstag, 27.09.2025 - Börsentäglich über 12.000 News
Hot Stock: KI-Boom treibt Kupfer in neue Dimensionen - jetzt profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZB | ISIN: US72941H5090 | Ticker-Symbol: XMP0
NASDAQ
26.09.25 | 21:59
0,615 US-Dollar
+9,18 % +0,052
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoPlus Therapeutics Pops on UNH Pact13
DoPlus Therapeutics-Aktie schießt nach Vereinbarung mit UnitedHealthcare in die Höhe 22
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
DoPlus Therapeutics stock soars after UnitedHealthcare agreement7
DoPlus Therapeutics rises on the back of UnitedHealthcare coverage deal7
DoPlus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit6
DoPlus Therapeutics Inc.: Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer224HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed...
► Artikel lesen
MoPlus Therapeutics receives $1.9M CPRIT payment for cancer program3
MoPlus Therapeutics receives $1.9 million payment from cancer research fund2
MoPlus Therapeutics Inc.: Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT2
18.09.Plus Therapeutics Inc.: Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide Diagnostics Clinical Laboratory190Certification critical to broad U.S. market release of the CNSide CSF Assay Platform CNSide now meets key federal and state regulatory requirements, including those set by the Centers for Medicare...
► Artikel lesen
03.09.Plus Therapeutics stock rating upgraded to Buy by D. Boral Capital4
26.08.Plus Therapeutics regains compliance with applicable Nasdaq listing criteria3
26.08.Plus Therapeutics regains Nasdaq compliance, extends bid price deadline3
26.08.Plus Therapeutics Inc.: Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria435HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform...
► Artikel lesen
26.08.Plus Therapeutics erfüllt wieder NASDAQ-Anforderungen an Börsenwert und Eigenkapital7
26.08.PLUS THERAPEUTICS, INC. - 8-K, Current Report2
22.08.PLUS THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans2
18.08.Plus Therapeutics Inc.: Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ in Leptomeningeal Metastases156REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting...
► Artikel lesen
15.08.Plus Therapeutics Reports $3M in Stock Equity3
15.08.Plus Therapeutics meets Nasdaq equity requirement to maintain listing10
Weiter >>
88 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2